HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards
HeartBeam (NASDAQ: BEAT) has been named a Rising Star in the 'Home Health Diagnostic' category at the 2024 Digital Health Hub Foundation Awards. The recognition was presented during the HLTH global healthcare conference for the company's innovative vector-based technology that captures heart electrical signals in three dimensions. The company's first application is a cable-free, credit card-sized device designed to synthesize a 12-lead ECG, currently under FDA review. HeartBeam holds 13 US patents and 4 international patents for its technology, which aims to provide comprehensive cardiac insights by leveraging AI analysis.
HeartBeam (NASDAQ: BEAT) è stata nominata Stella Nascente nella categoria 'Diagnostica per la Salute Domestica' agli Awards 2024 della Digital Health Hub Foundation. Il riconoscimento è stato presentato durante la conferenza globale sulla salute HLTH per la tecnologia innovativa a base di vettori dell'azienda che cattura i segnali elettrici del cuore in tre dimensioni. La prima applicazione dell'azienda è un dispositivo senza cavi delle dimensioni di una carta di credito progettato per sintetizzare un ECG a 12 derivazioni, attualmente in fase di revisione da parte della FDA. HeartBeam detiene 13 brevetti US e 4 brevetti internazionali per la sua tecnologia, che mira a fornire approfondimenti cardiaci completi sfruttando l'analisi AI.
HeartBeam (NASDAQ: BEAT) ha sido nombrada Estrella Emergente en la categoría de 'Diagnóstico de Salud en el Hogar' en los Premios 2024 de la Digital Health Hub Foundation. El reconocimiento fue presentado durante la conferencia global de salud HLTH por la innovadora tecnología basada en vectores de la compañía que captura las señales eléctricas del corazón en tres dimensiones. La primera aplicación de la compañía es un dispositivo sin cables del tamaño de una tarjeta de crédito diseñado para sintetizar un ECG de 12 derivaciones, actualmente bajo revisión de la FDA. HeartBeam posee 13 patentes en EE. UU. y 4 patentes internacionales para su tecnología, que tiene como objetivo proporcionar información cardiaca integral aprovechando el análisis de IA.
HeartBeam (NASDAQ: BEAT)는 2024 디지털 헬스 허브 재단 상에서 '가정 건강 진단' 분야의 신진 스타로 선정되었습니다. 이 인식은 HLTH 글로벌 의료 회의 중에 회사의 혁신적인 벡터 기반 기술이 심장 전기 신호를 3차원으로 포착하는 데 대해 수여되었습니다. 회사의 첫 번째 응용 제품은 케이블 없는 신용 카드 크기 장치로, 현재 FDA 검토 중인 12유도 ECG를 합성하기 위해 설계되었습니다. HeartBeam은 AI 분석을 활용하여 포괄적인 심장 정보를 제공하는 것을 목표로 하는 기술에 대해 미국 내 13개의 특허와 4개의 국제 특허를 보유하고 있습니다.
HeartBeam (NASDAQ: BEAT) a été nommé Étoile Montante dans la catégorie 'Diagnostic de Santé à Domicile' lors des Digital Health Hub Foundation Awards 2024. La reconnaissance a été présentée lors de la conférence mondiale sur la santé HLTH pour la technologie innovante de l'entreprise basée sur des vecteurs qui capture les signaux électriques du cœur en trois dimensions. La première application de l'entreprise est un dispositif sans fil de la taille d'une carte de crédit conçu pour synthétiser un ECG à 12 dérivations, actuellement en cours de révision par la FDA. HeartBeam détient 13 brevets américains et 4 brevets internationaux pour sa technologie, qui vise à fournir des informations cardiaques complètes en tirant parti de l'analyse par IA.
HeartBeam (NASDAQ: BEAT) wurde in der Kategorie 'Hausgesundheitsdiagnostik' beim Digital Health Hub Foundation Award 2024 als Rising Star ausgezeichnet. Die Auszeichnung wurde während der globalen Gesundheitskonferenz HLTH für die innovative vektorbasierten Technologie des Unternehmens verliehen, die elektrische Herzsignale in drei Dimensionen erfasst. Die erste Anwendung des Unternehmens ist ein , das derzeit von der FDA geprüft wird und für die Synthese eines 12-Kanal-EKGs entwickelt wurde. HeartBeam besitzt 13 US-Patente und 4 internationale Patente für seine Technologie, die umfassende kardiologische Erkenntnisse mithilfe von KI-Analysen bereitstellen soll.
- Technology recognized with Rising Star award in Home Health Diagnostic category
- Strong intellectual property portfolio with 13 US and 4 international patents
- FDA review in progress for innovative ECG device
- Product still pending FDA approval
- No current commercialization or revenue generation from main product
Company Receives Top Honors in the ‘Home Health Diagnostic’ Category for its Groundbreaking Technology that Captures the Heart’s Electrical Signals from Three Dimensions
“One of the main challenges in cardiac care is helping patients get the care they need in a timelier manner to prevent worse outcomes or an increased risk of death. This award is a validation of our dedicated team’s hard work to deliver a simple way for patients to capture high-fidelity ECG signals wherever they are when symptoms occur to minimize any delays in care,” commented Mr. Eno.
The recognition highlights HeartBeam’s use of cutting-edge digital innovations to achieve its mission of unlocking a more personalized approach to cardiac care. HeartBeam’s groundbreaking vector-based technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. By leveraging AI to analyze the data-rich signals, the Company believes it will be able to unlock a more personalized approach to cardiac care for patients.
The Company’s first application of its vector-based technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA. The Company has 13 issued US patents and 4 issued international patents supporting the underlying technology.
"The competition this year has been extraordinary, with thousands of submissions from groundbreaking companies worldwide,” said Mark H. Goldstein, Chairman and Founder of The Digital Health Hub Foundation. “We congratulate our winners whose innovations have truly impressed our esteemed panel of judges. The Digital Health Hub Foundation looks forward to witnessing the profound impact our champions continue to make in the healthcare space.”
The Digital Health Hub Foundation’s mission is to support the world’s most innovative healthcare companies in scaling and growing. Since 2017, the 30,000-member community has been dedicated to fostering innovation, including early-to-late-stage healthcare companies, industry providers, payors, mentors, and investors. The annual awards bring together the healthcare industry to celebrate and validate the best of the best in health technology.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024303708/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
What award did HeartBeam (BEAT) win at the 2024 Digital Health Hub Foundation Awards?
How many patents does HeartBeam (BEAT) currently hold for its cardiac technology?
What is HeartBeam's (BEAT) main product currently under FDA review?
